{"id":1404,"date":"2016-11-03T17:36:07","date_gmt":"2016-11-03T12:06:07","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1404"},"modified":"2021-07-24T12:56:34","modified_gmt":"2021-07-24T07:26:34","slug":"business-cocktail-7","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7","title":{"rendered":"Medivir &#038; Karo Pharma\u2019s deal; Astellas acquires Ganymed; Celldex Acquires Kolltan;  Allergan to Acquire Motus Therapeutics"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a08e31a5f9a5\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a08e31a5f9a5\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7\/#Medivir_entered_into_an_agreement_with_Karo_Pharma_to_sell_its_subsidiary_BioPhausia\" >Medivir entered into an agreement with Karo Pharma to sell its subsidiary BioPhausia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7\/#Astellas_to_acquire_German_company_Ganymed_Pharmaceuticals\" >Astellas to acquire German company Ganymed Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7\/#Celldex_Acquires_Kolltan_Pharmaceuticals\" >Celldex Acquires Kolltan Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7\/#Allergan_to_Acquire_Motus_Therapeutics\" >Allergan to Acquire Motus Therapeutics<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Medivir_entered_into_an_agreement_with_Karo_Pharma_to_sell_its_subsidiary_BioPhausia\"><\/span>Medivir entered into an agreement with Karo Pharma to sell its subsidiary BioPhausia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><strong>Medivir<\/strong> is set to sell is subsidiary, <strong>BioPhausia<\/strong>, to <strong>Karo Pharmafor\u00a0<\/strong>for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt free basis, including a normalized working capital, with the transaction expected to close by mid-December. <strong>BioPhausia<\/strong> comprises 13 established pharmaceutical drugs. From the third quarter of 2015 to the second quarter of 2016, <strong>BioPhausia<\/strong> posted revenues of Skr189m ($21m).<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Astellas_to_acquire_German_company_Ganymed_Pharmaceuticals\"><\/span>Astellas to acquire German company Ganymed Pharmaceuticals<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Japan\u2019s <strong>Astellas Pharma<\/strong> has signed an agreement to acquire German-based biopharmaceutical company <strong>Ganymed Pharmaceuticals <\/strong>for \u20ac1.2bn. With this transaction, <strong>Astellas<\/strong> will be able to continue to build upon its oncology franchise as a platform for sustainable growth. Under the agreement, <strong>Astellas<\/strong> will initially pay \u20ac422m to acquire 100% stake in <strong>Ganymed <\/strong>and <strong>Ganymed\u2019s<\/strong> shareholders will subsequently receive up to \u20ac860m based on progress in the IMAB362 clinical programme development.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Celldex_Acquires_Kolltan_Pharmaceuticals\"><\/span>Celldex Acquires Kolltan Pharmaceuticals<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><strong>Celldex Therapeutics <\/strong>has entered into a definitive agreement to acquire <strong>Kolltan Pharmaceuticals<\/strong>, a clinical-stage company focused on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases (RTKs), primarily in oncology. Clinical data has shown that <strong>Kolltan\u2019s<\/strong> drug candidates can help overcome tumor resistance mechanisms associated with current tyrosine kinase inhibitors. <strong>Celldex<\/strong> believes <strong>Kolltan\u2019s<\/strong> drug candidates and preclinical platform are compatible with the company\u2019s scientific approach and can be developed independently and in combination with <strong>Celldex\u2019s<\/strong> existing product candidates.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Allergan_to_Acquire_Motus_Therapeutics\"><\/span>Allergan to Acquire Motus Therapeutics<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Further building its gastrointestinal (GI) disease portfolio, <strong>Allergan<\/strong> plans to acquire <strong>Motus Therapeutics <\/strong>(formerly Rhythm Health), the GI-focused, wholly owned subsidiary of <strong>Rhythm Holding<\/strong>, for $200 million upfront plus an undisclosed sales milestone payment. The acquisition is the third in 5 weeks through which <strong>Allergan<\/strong> has expanded its GI offerings. <strong>Allergan<\/strong> had previously started plans to acquire <strong>Tobira Therapeutics<\/strong> for $1.695 billion and <strong>Akarna Therapeutics <\/strong>for $50 million. This acquisition is <strong>Allergan\u2019s<\/strong> third, which includes <strong>Motus\u2019 <\/strong>lead drug candidate, relamorelin (RM-131), a ghrelin agonist being developed for diabetic gastroparesis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Medivir entered into an agreement with Karo Pharma to sell its subsidiary BioPhausia Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor\u00a0for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt free basis, including a normalized working capital, with the transaction expected to close by mid-December. BioPhausia [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1201,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[2085,17390,17389,17391,17388],"industry":[17225],"therapeutic_areas":[],"class_list":["post-1404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-astellas-pharma","tag-celldex-therapeutics","tag-karo-pharma","tag-kolltan-pharmaceuticals","tag-medivir","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Medivir &amp; Karo Pharma\u2019s deal; Astellas acquires Ganymed<\/title>\n<meta name=\"description\" content=\"Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor\u00a0for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medivir &amp; Karo Pharma\u2019s deal; Astellas acquires Ganymed\" \/>\n<meta property=\"og:description\" content=\"Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor\u00a0for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-03T12:06:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09021755\/bi-case-study-pharmaceutical.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"372\" \/>\n\t<meta property=\"og:image:height\" content=\"296\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Medivir & Karo Pharma\u2019s deal; Astellas acquires Ganymed","description":"Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor\u00a0for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7","og_locale":"en_US","og_type":"article","og_title":"Medivir & Karo Pharma\u2019s deal; Astellas acquires Ganymed","og_description":"Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor\u00a0for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt...","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-11-03T12:06:07+00:00","article_modified_time":"2021-07-24T07:26:34+00:00","og_image":[{"width":372,"height":296,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09021755\/bi-case-study-pharmaceutical.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7","name":"Medivir & Karo Pharma\u2019s deal; Astellas acquires Ganymed","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09021755\/bi-case-study-pharmaceutical.jpg","datePublished":"2016-11-03T12:06:07+00:00","dateModified":"2021-07-24T07:26:34+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor\u00a0for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-7"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-7#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09021755\/bi-case-study-pharmaceutical.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09021755\/bi-case-study-pharmaceutical.jpg","width":372,"height":296},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09021755\/bi-case-study-pharmaceutical-300x239.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Astellas Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celldex Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Karo Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Kolltan Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Medivir<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Astellas Pharma<\/span>","<span class=\"advgb-post-tax-term\">Celldex Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Karo Pharma<\/span>","<span class=\"advgb-post-tax-term\">Kolltan Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Medivir<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 3, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 3, 2016 5:36 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1404"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1404\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1201"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1404"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1404"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}